Na ʻIkepili Peptide 
Mei 3, 2025
ʻO nā ʻatikala a me nā ʻike huahana i hāʻawi ʻia ma kēia pūnaewele pūnaewele wale nō no ka hoʻolaha ʻana i ka ʻike a me nā kumu hoʻonaʻauao.
ʻO nā huahana i hāʻawi ʻia ma kēia pūnaewele i manaʻo wale ʻia no ka noiʻi in vitro. Hana ʻia ka noiʻi in vitro (Latin: *i ke aniani*, ʻo ia hoʻi i ka ipu aniani) ma waho o ke kino kanaka. ʻAʻole kēia mau huahana he lāʻau lapaʻau, ʻaʻole i ʻae ʻia e ka US Food and Drug Administration (FDA), a ʻaʻole pono e hoʻohana ʻia no ka pale ʻana, mālama, a hoʻōla paha i kekahi maʻi olakino, maʻi, a i ʻole maʻi. Ua pāpā loa ʻia e ke kānāwai ke hoʻokomo i kēia mau huahana i loko o ke kino kanaka a holoholona paha ma kekahi ʻano.
Wehewehe kumu o ka Peptide Synthesis
ʻO ka peptide synthesis e pili ana i ke kaʻina hana o ke kūkulu ʻana i nā kaʻina amino acid a me ka hoʻokumu ʻana i nā paʻa amide (ʻo ia hoʻi, nā paʻa peptide) ma o ke ʻano kemika a i ʻole ke ʻano olaola, e hiki ai i ke kūkulu ʻana i ka oligopeptide a i ʻole polypeptide mole me nā hana koʻikoʻi. Ma ke ʻano he lālā koʻikoʻi o ke kemika bioorganic, ua kālele kēia ʻenehana i ka hoʻāla koho ʻana o nā monomers amino acid, conjugation kuhikuhi, a me ka mana pololei o ka hui pū ʻana, e hoʻopili ana i ka spectrum piha mai ka hoʻomākaukau ʻana o ka milligram-scale a hiki i ka hana ʻenehana kilokika. Ma muli o nā hoʻolālā synthetic divergent, ua hoʻokaʻawale ʻia ia i nā ʻano biosynthetic e hilinaʻi ana i nā ʻōnaehana biological a me nā ʻano synthesis kemika i hoʻokumu ʻia i nā loina synthesis organik. Ma waena o kēia mau mea, ua puka mai ka synthesis solid-phase ma ke ʻano he ala nui no ka hoʻomākaukau ʻana i nā lāʻau lapaʻau polypeptide a me nā peptides pae noiʻi ma muli o kona kiʻekiʻe kiʻekiʻe a hiki i ka automation. |
 |
Mechanism Molecular of Peptide Synthesis
ʻO ka synthesis kemika o nā kaulahao peptide e hahai ana i ka C-terminal a i ka N-terminal construction logic. E lawe i ka synthesis solid-phase ma ke ʻano he laʻana: ʻo nā ʻanuʻu kumu e komo mua i ka covalently heleuma i ka hui carboxyl o ka ʻakika amino hoʻomaka i kahi mea lawe resin insoluble, e ālai ana i nā ʻaoʻao ʻaoʻao ma o ka hoʻokomo ʻana i nā pūʻulu pale N-terminal, hoʻopau i ka N-terminal, a laila hui pū me nā derivatives amino acid i hoʻāla ʻia e hana i nā mea hoʻopaʻa peptide hou. Pono kēia kaʻina hana i ka mana pololei ma luna o ka orthogonality o nā pūʻulu pale kaulahao ʻaoʻao e pale aku i nā hopena nonspecific ma waena o nā pūʻulu hana. Ma hope o ka hōʻuluʻulu ʻana, ʻoki ʻia ka resin ma lalo o nā kūlana acidic ikaika a i ʻole nā kumu kumu, i ka manawa like me ka wehe ʻana i nā hui pale ʻaoʻao e loaʻa ai ka huahana peptide crude. ʻO ke ala biosynthetic, ma ka ʻokoʻa, hilinaʻi i nā ʻōnaehana ribosomal a i ʻole ribosomal synthetase, e loaʻa ana i ka biosynthesis o nā peptides kūlohelohe ma o ka mRNA template-mediated a i ʻole enzyme-catalytic domain assembly. Aia kona pono i ka hiki ke synthesize i nā kaulahao peptide ultra-long a me nā huahana kūlohelohe paʻakikī. |
 |
Nā ʻenehana koʻikoʻi i loko o nā kaʻina hana ʻo Peptide Synthesis
ʻO ka hoʻonui ʻia ʻana o nā kaʻina hana peptide synthesis e pili ana i ka hopena o ka hopena, ka hilinaʻi ʻana, a me ka scalability. Ma ka synthesis kemika, ʻo nā mea koʻikoʻi no ka hoʻonui ʻana i ka maikaʻi o ka hoʻohui ʻana a me ka hōʻemi ʻana i ka epimerization ke koho ʻana i nā reagents condensation, modulation o ka solvent polarity, a me ka mana pololei o ka wela o ka hopena. No ka hoʻoponopono ʻana i nā pilikia aggregation maʻamau i ka lōʻihi peptide synthesis, hiki ke hoʻokomo ʻia nā mea hoʻoheheʻe kōkua e like me HFIP, a i ʻole kahi hoʻolālā synthesis-ligation segmental. Ke hilinaʻi nei ka hoʻomaʻemaʻe ʻana i nā ʻenehana e like me ka reverse-phase high-performance liquid chromatography (RP-HPLC) a me ka gel filtration chromatography, me ka hōʻoia ʻana o ke kūkulu ʻana i loaʻa ma o mass spectrometry (MS) a me ka nuclear magnetic resonance (NMR). Hoʻopili nā ʻōnaehana hoʻokele maikaʻi i ka hoʻomaʻemaʻe chiral o nā waikawa amino, ka hoʻoholo ʻana i ka peptide content, a me ka nānā ʻana i ka ʻikepili haumia e hōʻoia i nā huahana e hoʻokō i nā kūlana lāʻau lapaʻau a noiʻi paha. No nā kaʻina hana biosynthetic, aia nā hana koʻikoʻi i ka hoʻololi ʻana i nā cell host, hoʻomaikaʻi i ka hōʻike peptide target a me ka solubility ma o ka codon optimization a me ke kūkulu ʻana i ka ʻōnaehana huna huna, ʻoiai ka hoʻohui ʻana i ka hoʻokaʻawale ʻana a me nā ʻenehana hoʻomaʻemaʻe no ka hana ʻoihana.
Waiwai Multidimensional a me ka hoohana ana o Synthetic Peptides
Hoʻokani nā peptides synthetic i nā hana hiki ke hoʻololi ʻia i ka biomedicine, ka ʻepekema waiwai, a me ka noiʻi kumu. Ma ka lāʻau lapaʻau, nā lāʻau polypeptide-i hōʻike ʻia e ka kikoʻī kiʻekiʻe, ka haʻahaʻa haʻahaʻa, a me ka biodegradability-e lawelawe i nā mea lapaʻau koʻikoʻi no nā maʻi e like me ka maʻi diabetes. I loko o nā antibody-drug conjugates (ADCs), hoʻohana nā peptides linker i ka hana nui o ka hāʻawi ʻana i nā uku cytotoxic. I ka biotechnology, hoʻohana ʻia nā peptides synthetic ma ke ʻano he antigen epitopes no ka hoʻomohala ʻana i ka antibody, ma ke ʻano he ligands no ke aʻo ʻana i nā pilina receptor-ligand, a i ʻole he substrates enzyme no ka wehe ʻana i nā mīkini catalytic. I ka ʻepekema waiwai, hiki i nā peptides hana ke hoʻohui iā lākou iho i nā mea biocompatible e like me nā nanofibers a me nā hydrogels, i hoʻopili ʻia i nā scaffolds ʻenekinia kiko a i ʻole nā vector lawe lāʻau. Eia kekahi, ma o ka hoʻololi kemika a i ʻole ka hoʻohui ʻia ʻana o nā waikawa amino kūlohelohe ʻole, hiki i nā peptides synthetic ke hoʻohālike i nā kikowaena hana o nā protein kūlohelohe, e hāʻawi ana i nā kumu hoʻohālike kūpono no ke aʻo ʻana i ka pilina o ka hana protein a me ka holomua ʻana i nā palena i ka lāʻau lapaʻau pololei a me ka biology kemika.
